The B Kristine Johnson Declaration Trust, affiliated with an AtriCure, Inc. director, filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 2,452 shares of AtriCure common stock on NASDAQ.

Key Highlights

  • Seller: B Kristine Johnson Declaration Trust, identified as a Director-affiliated account, with Beth Kristine Johnson signing as Trustee.
  • Shares proposed for sale: 2,452 shares of AtriCure, Inc. common stock.
  • Aggregate market value: $143,397.13, according to the filing.
  • Shares outstanding: 50,922,283 shares of common stock, as reported in the filing.
  • Acquisition history: The shares were acquired on May 20, 2021, via restricted stock vesting under a registered plan, with services rendered as the nature of payment.
  • No sales in past 3 months: The filing reports nothing to report under securities sold during the prior three months.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

AtriCure Director-Affiliated Trust Proposes Rule 144 Sale of Restricted Stock

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, the B Kristine Johnson Declaration Trust intends to sell 2,452 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC), with an approximate sale date of November 6, 2026. The filing identifies the trust's relationship to the issuer as that of a Director, and Beth Kristine Johnson signed the notice as Trustee.

The filing discloses that the shares to be sold were originally acquired on May 20, 2021, through restricted stock vesting under a registered plan, with the issuer listed as the person from whom the securities were acquired. The nature of payment is listed as "Services Rendered," and the date of payment matches the acquisition date of May 20, 2021. The aggregate market value of the proposed sale is stated as $143,397.13, based on 2,452 shares.

AtriCure, Inc. is headquartered at 7555 Innovation Way, Mason, Ohio 45040, and carries SEC File Number 000-51470. The filing states that no securities of AtriCure were sold by the trust in the three months preceding this notice. The proposed transaction is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. By signing the notice, the trustee represented that no material adverse information regarding AtriCure's current and prospective operations, beyond what has been publicly disclosed, is known to the person for whose account the securities are to be sold.

What Was Disclosed

A Form 144 notice was filed on November 6, 2026, disclosing a proposed sale of 2,452 AtriCure common shares, with an aggregate market value of $143,397.13, by the B Kristine Johnson Declaration Trust, a Director-affiliated account. No sales were reported in the prior three months.